Compugen Ltd. (NASDAQ:CGEN) Stock Rated “Buy” by Wall Street Brokerages

Compugen Ltd. (NASDAQ:CGEN) has received a consensus rating of “Buy” from the five analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $5.00.

A number of equities research analysts recently issued reports on CGEN shares. Weiss Ratings restated a “hold (c-)” rating on shares of Compugen in a report on Tuesday, November 3rd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Compugen in a research note on Monday, October 12th.

Compugen Price Performance

CGEN opened at $2.09 on Thursday. The stock has a market capitalization of $197.62 million, a price-to-earnings ratio of 5.36 and a beta of 2.85. The business has a 50-day moving average of $2.22 and a two-hundred day moving average of $2.29. Compugen has a 12 month low of $1.43 and a 12 month high of $3.23.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Monday, November 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.02. Compugen had a net margin of 47.90% and a return on equity of 39.30%. The business had revenue of $3.82 million for the quarter, compared to analyst estimates of $1.28 million. During the same period in the prior year, the firm posted ($0.07) EPS. Equities research analysts anticipate that Compugen will post -0.28 earnings per share for the current year.

Institutional Trading of Compugen

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Joel Isaacson & Co. LLC raised its position in shares of Compugen by 291.7% in the 3rd quarter. Joel Isaacson & Co. LLC now owns 47,000 shares of the biotechnology company’s stock worth $112,000 after buying an additional 35,000 shares during the period. WINTON GROUP Ltd boosted its holdings in Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company’s stock valued at $422,000 after acquiring an additional 40,614 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Compugen during the second quarter valued at about $110,000. Glenmede Trust Co. NA grew its position in Compugen by 187.5% during the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 22,500 shares during the period. Finally, Renaissance Technologies LLC grew its position in Compugen by 12.1% during the first quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after acquiring an additional 176,088 shares during the period. 12.22% of the stock is currently owned by institutional investors and hedge funds.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is an Israeli clinical-stage biotechnology company focused on discovering and developing novel therapeutic and drug targets for cancer and other diseases. The company uses computational biology and artificial intelligence-based approaches to identify previously unrecognized biological mechanisms and translate them into potential medicines. Compugen’s research has primarily centered on immuno-oncology, with an emphasis on regulating immune responses within the tumor microenvironment.